Product Overview
[Drug name]
Generic name: Enalapril Maleate Tablets
Trade name: Shutuo
English name: Enalapril Maleate Tablets
Chinese Pinyin: Malaisuan Yinapuli Pian
[Ingredients]
Enalapril Maleate
[Properties]
White tablets
[Indications]
For the treatment of essential hypertension.
[Usage and Dosage]
The starting dose is 5-10 mg per day, taken orally in 1-2 times. For patients with severe renal impairment (creatinine clearance less than 30 ml/min), it is 2.5 mg per day. The dose can be gradually increased according to the blood pressure level. The general effective dose is 10-20 mg per day. The maximum daily dose should not exceed 40 mg. It can be used in combination with other antihypertensive drugs, especially diuretics, and the antihypertensive effect is significantly enhanced, but it should not be used in combination with potassium-retaining diuretics.
[Adverse reactions]
There may be dizziness, headache, drowsiness, dry mouth, fatigue, upper abdominal discomfort, nausea, chest tightness, cough, rash, flushing and proteinuria. Reduce the dose if necessary. If leukopenia occurs, stop the drug.
[Contraindications]
Patients who are allergic to this product or have bilateral renal artery stenosis should not use it. Children, pregnant women, breastfeeding women, and those with severe renal impairment should use it with caution.
[Precautions]
1. Some patients, especially those who use diuretics or have reduced blood volume, may cause excessive drop in blood pressure, so the first dose should start with 2.5 mg.
2. Regularly measure white blood cell count, renal function and blood potassium.
[Special population medication]
Precautions for children: Use with caution in children.
Precautions for pregnancy and lactation: Use with caution in pregnant women and breastfeeding women.
Precautions for the elderly: This experiment has not been conducted and there are no reliable references.
[Drug interactions]
1. Antihypertensive treatment This product may have an additive effect when used simultaneously with other antihypertensive treatments. 2. Serum potassium 2.1 In clinical trials, serum potassium is generally kept within the normal range. After 48 weeks of using enalapril maleate alone to treat hypertensive patients, it can be seen that the average increase in serum potassium is about 0.2 mg equivalent/ml. In patients treated with enalapril maleate plus a thiazide diuretic, the potassium-excreting effect of the diuretic is often attenuated by the effect of enalapril. 2.2 The use of enalapril maleate and potassium-excreting diuretics can reduce diuretic-induced hypokalemia. 2.3 Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and concomitant use of potassium-storing diuretics (such as spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes. 2.4 The use of potassium supplements, potassium-storing diuretics, or potassium-containing salt substitutes (especially in patients with renal insufficiency) can cause a significant increase in serum potassium. 2.5 If the concomitant use of the above agents is considered appropriate, use them with caution and monitor serum potassium frequently. 3. Serum lithium As with other sodium-excreting drugs, lithium clearance may be reduced. Therefore, if lithium salts are taken, serum lithium concentrations should be carefully monitored. 4. Non-steroidal anti-inflammatory drugs For some patients with renal insufficiency, the combination of angiotensin converting enzyme inhibitors and non-steroidal anti-inflammatory drugs may lead to further decline in renal function. This effect is usually reversible.
[Pharmacological action]
Angiotensin converting enzyme inhibitors. After oral administration, it is hydrolyzed into enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on dinephrogenic hypertension, uninephrogenic hypertension and spontaneous hypertension rat models.
[Storage]
Shade from light and store in a sealed container.
[Specification]
5mg
[Packaging specification]
5mg*16s/box
[Validity period]
36 months
[Approval number]
National medicine standard H20083533
[Manufacturer]
Company name: Shanghai Xinya Pharmaceutical Minhang Co., Ltd.
